Cell Therapy Market Assessment, Size, Value, Share, Growth, Trends, Competition, Industry Analysis, Actionable Insights Report; By Therapy Type, By Therapeutic Area, By End-User, By Region and By Country; Outlook and Forecasts, 2024 – 2030

Report Summary

The Global Cell Therapy Market is projected to grow at a CAGR of 16% over the forecast period (2024 – 2030). Cell Therapy Market size was valued at USD 11 billion in 2023 and is projected to reach about USD 40 billion in 2030. The Cell Therapy Market is majorly driven by the increasing number of clinical studies for cell-based therapies. This has also resulted in a substantial global investment in research and their clinical translation over the forecast period.

Cell Therapy Market Overview and Insights

Cell therapy is defined as the transplantation of human cells in order to replace or repair damaged tissue or cells. Also, with new technologies, innovative products, and limitless imagination, many different types of cells have been used as part of a therapy or treatment for a variety of diseases and conditions. Stem cells serve as the primary cells for advanced therapies due to their unique capability to transform into precise cells essential for repairing damaged or malfunctioning tissues or cells. The market for cell therapy is constantly growing to include new cell types, which presents a significant opportunity for companies to strengthen their market positions. The high adoption of numerous CAR-T Cell therapies owing to their favorable outcomes for the treatment of various types of cancers and genetic disorders has also boosted the cell therapy market. Consequently, over recent years, there has been a significant surge in the number of companies dedicated to developing cell therapies. Increased funding for clinical studies in cell therapy, the implementation of effective manufacturing guidelines, and the success of innovative products stand as major influencers driving market growth.

The rising number of ongoing clinical trials can be due to the presence of government and private funding agencies that are constantly offering grants to support projects across various stages of clinical trials. This has boosted the cell therapy market growth over the forecast period. Also, the field of regenerative medicine is witnessing series of advancements, further expected to offer effective treatment solutions for chronic ailments.

What are the Cell Therapy Market Segmentations and Bifurcations?

Cell Therapy Market Segments based on Therapy Type

• Autologous Cell Therapy
  • Others
• Stem Cell Therapies
  • BM, Blood, & Umbilical Cord-derived Stem Cells
  • Adipose derived cells
  • Others
• Non-Stem Cell Therapies
  • T-Cell Therapies
    • CAR T Cell Therapy
    • T Cell Receptor (TCR)-based
• Allogenic Cell Therapy
• Stem Cell Therapies
  • Hematopoietic Stem Cell Therapies
  • Mesenchymal Stem Cell Therapies
• Non-Stem Cell Therapies
  • Keratinocytes & Fibroblast-based Therapies
  • Others

In 2023, the cell therapy market was prominently led by the autologous cell therapy segment, securing a commanding 70% revenue share. This dominance stems from the numerous advantages inherent in autologous transplants. These include enhanced accessibility, elimination of the need to identify an HLA-matched donor, reduced risk of life-threatening complications, absence of GVHD risk, and no requirement for immunosuppressive therapy. Forecasts indicate this segment will continue its rapid growth due to its widespread adoption, supported by its cost-effectiveness compared to allogenic therapies.

The surge in this segment owes much to the increased utilization of CAR-T therapies, showing promising outcomes in treating various cancers and genetic disorders. Some of these therapies have gained FDA approval, with ongoing efforts to expand their adoption. Notably, the FDA recently approved ciltacabtagene autoleucel (Carvykti) for adults with refractory or relapsed multiple myeloma, targeting previously unresponsive illnesses.

Looking ahead, the allogeneic cell therapy segment anticipates substantial expansion between 2024 and 2030 within the global cell therapy industry. This growth is propelled by its extensive adoption in formulating innovative therapeutic approaches.

Cell Therapy Market Segments based on Therapeutic Area

• Oncology
• Cardiovascular Disease (CVD)
• Musculoskeletal Disorders
• Dermatology & Wounds
• Autoimmune Disorders
• Others

In 2023, the oncology segment claimed a commanding 40% revenue share in the cell therapy market. Notably, CAR T-cells targeting CD19 exhibited remarkable efficacy, offering high rates of complete and enduring remissions in patients with Acute Lymphocytic Leukemia (ALL). The prospect of increased FDA approvals for innovative therapies signals potential growth opportunities within the cell therapy industry.

Recent FDA approval of brexucabtagene autoleucel (Tecartus) for individuals with refractory B-cell precursor or relapsed conditions marks a significant milestone. This approval positions brexucabtagene as the pioneering CAR-T treatment for adult ALL (acute lymphocytic leukemia) patients.

Looking forward, the musculoskeletal disorders segment anticipates substantial market expansion. Ongoing research focuses on developing technologies that facilitate the regeneration or repair of damaged musculoskeletal tissues. Various research entities are examining clinically viable cell types for therapies aimed at remedying musculoskeletal tissue degeneration. The application of engineered or native skeletal progenitor cells shows promise in directly triggering tissue repair and revitalizing musculoskeletal tissues.

Cell Therapy Market Segments based on End-User

• Hospitals and Clinics
• Academic and Research

During the forecast period, the hospitals & clinics segment is poised for the most significant CAGR among end users. This growth trajectory is primarily driven by a surge in pipeline projects and clinical trials. Cell therapy finds extensive application in various therapeutic areas, including malignancies, musculoskeletal therapies, autoimmune disorders, and dermatology, contributing to its substantial use in treatment and diagnostics.

What are the Growth Drivers, Restraints, and Opportunities in Cell Therapy Market?

Rising Incidence of Chronic Disorders and Infections Propels Cell Therapy Market Growth

The growth of the cell therapy market has been significantly bolstered by the increasing prevalence of chronic diseases and infections. This surge is attributed to the versatile applications of cell therapy, encompassing diagnostic purposes and clinical research linked to conditions such as HIV/AIDS, cancer, and various infectious diseases. 

Additionally, the escalating incidence of diabetes contributes substantially to market expansion. According to the International Diabetes Federation Diabetes Atlas, nearly 570 million individuals worldwide were affected by diabetes in 2022, with projections indicating an increase to 780 million by 2045.

New Technologies Boost Growth in Cell Therapy Market

The ascent of the cell therapy market is significantly propelled by the gradual emergence of new technologies aimed at supporting advanced therapy development. The introduction of proprietary cell lines stands out as a key approach, enabling the generation of a diverse portfolio of candidates from a single product. Continual advancements in cell engineering, gene editing, and manufacturing platforms, including 3D bioprinting, are broadening the therapeutic scope of cell therapies. These advancements facilitate enhanced targeting, reduced side effects, and the realization of personalized treatment options.

The industry foresees the potential development of around 60 new cell therapies in the upcoming years, potentially benefiting over 300,000 patients in the United States exclusively. This trajectory underscores the dynamic evolution and promising future of cell-based treatments. Moreover, with a substantial global cohort exceeding 1,000 companies dedicated to advanced therapeutics and nearly 2,000 ongoing cell or gene therapy clinical studies in pipeline, the market braces itself for a potential upswing in approvals.

Government Reimbursements, Regulatory Approvals, and Private Investments Drive Cell Therapy Market Growth 

Regulatory bodies, such as the FDA, are progressively embracing cell therapy products, evident in the increasing number of granted approvals for these therapies. The evolution of regulatory frameworks globally has delineated clearer pathways for the development and commercialization of cell-based treatments. Collaborative efforts between regulatory agencies and stakeholders are establishing guidelines focused on ensuring safety and efficacy, thereby streamlining the approval processes.

Simultaneously, evolving reimbursement policies are enhancing access for certain patient cohorts, mitigating barriers posed by the high costs associated with cell therapies. Despite their expense, evolving reimbursement policies from both private and public insurers are broadening patient access.

Substantial investments from both governments and private entities are driving accelerated research and commercialization efforts in cell therapy. This infusion of funds crucially supports clinical trials, bolsters manufacturing infrastructure, and facilitates talent acquisition.

However, the high cost of cell therapies remains a significant challenge restraining the expansion of the global cell therapy market. Additionally, the scarcity of skilled professionals presents another hurdle to market growth. Nevertheless, given the wide-ranging applications of cell therapy, the global market is poised for growth in the near future, despite these challenges.

Cell Therapy Report Scope & Snapshot

What are the Regional and Country Trends in Cell Therapy Market?

Cell Therapy Market - Regional Landscape and Trends

• North America
• Europe
• Asia Pacific
• Middle east and Africa
• South America

In 2023, North America claimed more than 50% share of the global cell therapy market, marking its dominance. This is primarily attributed to collaborative research initiatives between research institutes and major pharmaceutical entities within the region. Ongoing collaborations continue to drive significant advancements, supported by escalating investments from market players. The United States, in particular, stands as a leading country propelling market growth in North America throughout the forecast period.

A recent collaboration between Immatics and Bristol Myers Squibb to develop Gamma Delta Allogeneic Cell Therapy Programs illustrates the vigor in this domain. This initiative involves the creation of two programs by Bristol Myers Squibb, with both companies having the option to develop up to four additional programs each. Enhanced efficacy of cell therapy products in treating cancers is anticipated to spur heightened product development, consequently fueling market growth.

Asia Pacific cell therapy market is projected to register the fastest CAGR during the forecast period. This acceleration is underpinned by surging demand for cell therapy in the region. Factors such as heightened awareness about novel therapies, increased investments, and anticipated favorable governmental policies are set to propel market expansion.

How is the Competition Scenario in Cell Therapy Market?

Cell Therapy Market - Competitive Landscape

Companies in the cell therapy market are implementing diverse strategies to expand their customer base, targeting surgeons to promote usage in transplantation procedures. Additionally, these firms are actively engaged in initiatives such as new product launches, collaborations, partnerships, mergers, and acquisitions to fortify their market positions. Notable players in cell therapy industry include (but are not limited to) Anterogen Co. Ltd, Atara Biotherapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb Company, Castle Creek Biosciences Inc., Celgene Corporation, Cells for Cells, Chiesi Farmaceutici S.p.A., Corestem Inc., Dendreon Corp., Gilead Sciences, Inc., JCR Pharmaceuticals Co., Ltd., Johnson & Johnson Services, Inc., Kolon TissueGene Inc., Medipost, Nipro, Novartis AG, NuVasive Inc., Pharmicell, Stempeutics, Tameika Cell Technologies Inc., Tego Science, and TiGenix (Takeda), among others.

Cell Therapy Industry Developments

• In August 2023, NKGen Biotech announced the commencement of Phase I clinical trials, dosing the first patient with SNK02, an allogeneic NK cell therapy designed for treating solid tumors.
• In June 2023, Quell Therapeutics entered a strategic license agreement with AstraZeneca. This collaboration aims to develop, manufacture, and commercialize engineered Treg cell therapies specifically tailored for autoimmune disorders.
• In June 2023, SCTbio joined forces with Cyto-carein to enhance cryopreservation quality for cell therapy development in Europe.
• In June 2023, Bristol Myers Squibb it received FDA approval for its recently launched, state-of-the-art cell therapy production facility in Devens, Massachusetts. This expansion is projected to bolster BMS’ global cell therapy manufacturing footprint, ensuring a sustained supply of cell therapy products.
• In April 2023, Bristol Myers Squibb collaborated with Novartis to fortify cell therapy capabilities, introducing a U.S. manufacturing facility dedicated to viral vector production for CAR T cell therapies.
• In March 2023, Thermo Fisher Scientific Inc. collaborated with Arsenal Biosciences Inc. to pioneer manufacturing processes for innovative cancer treatments. This focused collaboration has empowered ArsenalBio to craft a robust manufacturing system for their next-generation, programmable autologous T cells tailored for cancer treatment.
• In March 2023,, Danaher forged a partnership with the University of Pennsylvania's Center for Cellular Immunotherapies. This strategic alliance aims to address manufacturing challenges hindering the widespread adoption of cell therapies, focusing on resolving critical production hurdles.
• In March 2023, Lonza and Vertex embarked on a strategic collaboration to streamline the manufacturing process for Vertex's investigational stem cell-derived islet cell therapies. This collaboration entails establishing a dedicated manufacturing facility aimed at enhancing the production of T1D cell therapies within Vertex's portfolio.
• In January 2023, Kite, a Gilead Company, strategically partnered with Arcellx, Inc. to jointly develop and commercialize CART-ddBCMA, focusing on treating relapsed multiple myeloma.
• In December 2022, Kite completed the acquisition of Acquire Tmunity Therapeutics with a focus on advancing Next-Generation CAR T-Cell therapies in cancer treatment. This strategic acquisition provides Kite with access to a portfolio of pre-clinical and clinical projects. Notably, it includes an 'armored' CAR T technology platform designed to enhance anti-tumor efficacy across a spectrum of CAR Ts. Moreover, this acquisition is anticipated to streamline production procedures, ensuring quicker and more efficient development processes for these therapies.
• In June 2022, Novartis collaborated with the American Society of Hematology to advance standard-of-care screening practices and enhance existing therapies for sickle cell disease in Sub-Saharan Africa.
• In May 2022, the FDA granted approval for Novartis' Kymriah® CAR-T cell therapy, specifically for patients experiencing relapsed or refractory follicular lymphoma. 
• In April 2022, Kite expanded its operations in Maryland, focusing on the development of CAR T-Cell Therapy. This expansion coincided with FDA approval for the commercial manufacturing of CAR T-cell therapy tailored for blood cancer.